加载中
NASDAQHealthcareBiotechnology
最新数据
US$129.31
−US$5.07 · -3.77%
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
常规交易时段
US$129.31
−US$5.07 · -3.77%
盘中时间采用ET。市场数据可能有所延迟。
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
日内区间
当前US$129.31
52周区间
当前US$129.31
盘中时间采用ET。市场数据可能有所延迟。
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
日内区间
当前US$129.31
52周区间
当前US$129.31
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 2590.2万 USD | 3141.8万 USD |
| 销货成本 | — | — | — | 278万 USD | 236.8万 USD |
| 毛利 | — | — | — | 2312.2万 USD | 2905万 USD |
| 研究与开发 | 2284.1万 USD | 815.1万 USD | 879.3万 USD | 5021.2万 USD | 6419.7万 USD |
| 销售、一般及管理费用 | 1576.1万 USD | 594.4万 USD | 307.6万 USD | 1638.4万 USD | 1668.4万 USD |
| 营业费用 | 3860.2万 USD | 1409.5万 USD | 1186.9万 USD | 6659.6万 USD | 8088.1万 USD |
| 利息收入 | 259万 USD | 64.2万 USD | 626.5万 USD | 72.1万 USD | 4000 USD |
| 利息支出 | 581.8万 USD | 431.7万 USD | — | — | — |
| 折旧和摊销 | — | — | — | 278万 USD | 236.8万 USD |
| 营业利润 | −3860.2万 USD | −1409.5万 USD | −1186.9万 USD | −4347.4万 USD | −5183.1万 USD |
| 净利润 | −4171.5万 USD | −1743.4万 USD | 1869.1万 USD | −3327.7万 USD | −4573.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$229
上涨空间 77.09%价格历史记录不可用
最高：US$246平均的：US$229最低：US$207| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年4月23日 | 1:80 | — | — |
已生效 2024年4月23日
1:80
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
